Compare Bank of Nova Scotia (BNS) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Nova Scotia vs Mesoblast Limited — how do they compare? Bank of Nova Scotia trades at $89.03 (market cap $107.95B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Bank of Nova Scotia is far larger — about 50× Mesoblast Limited's market cap, and Bank of Nova Scotia pays a 3.65% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| BNS | MESO | |
|---|---|---|
Market Cap | $107.95B | $2.16B |
Sector | Financials | Technology |
52-Week High | $90.29 | $20.96 |
52-Week Low | $56.41 | $12.88 |
Dividend Yield | 3.65% | — |
Enterprise Value | — | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of Nova Scotia (BNS) trades at $88.85, up 0.6% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong analyst support, a 52.63% buy rating, and a solid dividend yield. Revenue grew to $37.10B in 2025, though net income margin dipped slightly to 20.99%.
Outlook is positive with earnings growth and strategic acquisitions like MapleMark Bank driving upside. Risks include economic sensitivity and competitive pressures. Wall Street sentiment leans bullish, but investors should monitor credit conditions and interest rate impacts on banking performance.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
